Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in IDH-Mutant Gliomas With and Without Hypermutator Phenotype
NCT03718767Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2019
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in glioma, sponsored by National Cancer Institute. Primary endpoint: Median Progression Free Survival Rate at 6 months. Started Mar 2019; status: active, not recruiting.
02
Drugs
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03718767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718767.